Latest Drug Development News

Page 10 of 29
Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.
Ada Torres
Ada Torres
25 Feb 2026
Neurotech International has reported positive long-term safety results for its lead drug candidate NTI164, bolstering its path towards regulatory approval and chronic use in paediatric neurological disorders.
Ada Torres
Ada Torres
23 Feb 2026
Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.
Ada Torres
Ada Torres
17 Feb 2026
Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.
Ada Torres
Ada Torres
12 Feb 2026
Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.
Ada Torres
Ada Torres
12 Feb 2026
Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.
Victor Sage
Victor Sage
11 Feb 2026
Paradigm Biopharmaceuticals has published a pivotal study in PLOS ONE showing sustained pain relief and joint repair in dogs treated with pentosan polysulfate sodium, reinforcing its potential for human osteoarthritis therapy.
Ada Torres
Ada Torres
11 Feb 2026
Racura Oncology has developed a pioneering blood test that promises to fast-track key data on its cardioprotective drug RC220, potentially shaving two years off the clinical trial timeline. This innovation also enhances patient safety and recruitment prospects in the ongoing RAC-010 CPACS trial.
Ada Torres
Ada Torres
11 Feb 2026
Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.
Ada Torres
Ada Torres
11 Feb 2026
Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.
Ada Torres
Ada Torres
11 Feb 2026
Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.
Ada Torres
Ada Torres
10 Feb 2026
Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.
Victor Sage
Victor Sage
9 Feb 2026

Browse the archive

Full archive